Genentech said Friday the U.S. Food and Drug Administration has approved an update to the Rituxan (rituximab) label to include information on follow-up treatment of adult patients with certain forms of vasculitis, or blood vessel inflammation.

The label update was based on data from a Roche-supported study by the French Vasculitis Study Group showing that treatment with the rituximab regimen resulted in fewer major relapses by month 28 compared to treatment with azathioprine.

Genentech is a member of the Roche Group.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

October 19, 2018 12:11 ET (16:11 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Roche (QX) Charts.